Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50)”
From Hypoglycemia (2018) · cites this paper as [48]
In the citing paper
“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [127]
In the citing paper
“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“In addition, regulatory hurdles from the US FDA, despite pivotal trials done by the Collaborative Islet Transplant group, 62 have been a major stumbling block for the development of islet transplantation technology in the USA.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“5,000 islet equivalents (IEQ)/kg for the first dose and $4,000 IEQ/kg for subsequent doses (if any), was prepared from a single pancreas (14) and was transplanted by portal vein infusion.”
MethodResultSelf-citationStandards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651 · cited 1×
“Recipient Selection Inclusion criteria included the following: age 18–65 years; T1D for $5 years; absent stimulated C-peptide; IAH and/ or marked glycemic lability (19,20); and a history of SHEs in the prior 12 months despite medical care provided by an endocrinologist or diabetologist, who asserted that the candidate…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Items 201–300 of 705
Rios, P., Skoumal, M., Liu, J. M.-H., Youngblood, R. L., Kniazeva, E., García, A. J., & Shea, L. D. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26741 · Cited by 23
“Alternatively, islet transplantation into the hepatic portal vein has been used to restore endogenous insulin production and aid in maintenance of normoglycemia and the prevention of severe hypoglycemic events (Gibly, Graham et al., 2011; Hering et al., 2016).”
BackgroundJamison, B. L., DiLisio, J. E., Beard, K. S., Neef, T., Bradley, B., Goodman, J., Gill, R. G., Miller, S. D., Baker, R. L., & HASKINS, K. M. (2022) · Diabetes · doi:10.2337/db20-1170 · Cited by 23
Innovative immunotherapies and emerging treatments in type 1 diabetes management
Zarei, M., Sheikholeslami, M. A., Mozaffari, M., & Mortada, Y. (2024) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2024.100247 · Cited by 23
Single-donor islet transplantation in type 1 diabetes: patient selection and special considerations
Tatum, J. A., Meneveau, M. O., & Brayman, K. L. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s105692 · Cited by 23
“D ec -2 01 8 F or p er so na l u se o nl y. Powered by TCPDF (www.tcpdf.org) 1 / 1 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10 submit your manuscript | www.dovepress.com Dovepress Dovepress 75 Single-donor islet transplantation in type 1 diabetes of hypoglycemic events post-transplant.18 This…”
MethodKenyon, N. S., Willman, M. A., Han, D., Kronenfeld, R. S., Rabassa, A., Díaz, W., Geary, J. C., Poumian-Ruiz, E., Griswold, A. J., Booven, D. J. V., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16693 · Cited by 23
“POD 0 (4) POD 0 + IV (5) Delayed IV (4) (A)”
Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease
Hu, X., Beauchesne, P. R., Wang, C., Wong, A. W., Deuse, T., & Schrepfer, S. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.009 · Cited by 22
Ajima, K., Tsuda, N., Takaki, T., Furusako, S., Matsumoto, S., Shinohara, K., Yamashita, Y., Amano, S., Oyama, C., & Shimoda, M. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100370 · Cited by 23
Saravanan, P. B., Kanak, M. A., Chang, C., Darden, C. M., Yoshimatsu, G., Lawrence, M. C., & Naziruddin, B. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14615 · Cited by 22
Onaca, N. N., Takita, M., Levy, M. F., & Naziruddin, B. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000977 · Cited by 22
Maenaka, A., Kinoshita, K., Hara, H., & Cooper, D. K. C. (2023) · Xenotransplantation · doi:10.1111/xen.12802 · Cited by 21
Abdulreda, M. H., Berman, D. M., Shishido, A., Martin, C., Hossameldin, M., Tschiggfrie, A., Hernandez, L. F., Hernandez, A., Ricordi, C., Parel, J.-M. A., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4814-4 · Cited by 21
“This is in line with clinical data from individuals with type 1 diabetes showing significant improvement in quality of life through better glycaemic control following intrahepatic islet transplantation, and even after resumption of insulin therapy due to graft failure [1, 27].”
Self-citationKhiatah, B., Qi, M., Wu, Y., Chen, K.-T., Perez, R. G., Valiente, L., Omori, K., Isenberg, J. S., KANDEEL, F. R., Yee, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45678-y · Cited by 21
Spiers, R. M., Marzi, J., Brauchle, E., Cross, S. E., Vaughan, R. H., Bateman, P. A., Hughes, S. J., Schenke‐Layland, K., & Johnson, P. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.013 · Cited by 21
Pancreas transplantation today: quo vadis?
Al-Naseem, A., Attia, A., Gonnah, A. R., Al-Naseem, A. O. A. S., Spiers, H. V. M., Gruessner, A. C., Leelarathna, L., Thabit, H., & Augustine, T. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad032 · Cited by 21
Qi, M., Bilbao, S., Forouhar, E., KANDEEL, F. R., & Al-Abdullah, I. H. (2017) · Cell and Tissue Banking · doi:10.1007/s10561-017-9659-9 · Cited by 21
“Replacement of destructed b-cells by transplanting islets from human cadaveric pancreata achieves euglycemia and insulin independence in subsets of patients with type 1 diabetes (Hering et al. 2016; Ricordi et al. 2016).”
BackgroundThe Current Status of Bioartificial Pancreas Devices
Photiadis, S. J., Gologorsky, R. C., & Sarode, D. N. (2020) · ASAIO Journal · doi:10.1097/mat.0000000000001252 · Cited by 21
Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge
Caldara, R., Tomajer, V., Monti, P., Sordi, V., Citro, A., Chimienti, R., Gremizzi, C., Catarinella, D., Tentori, S., Paloschi, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1323439 · Cited by 20
“Numerous studies, often conducted on limited patient cohorts, have proposed a variety of immunosuppressive agent combinations (59, 231 – 233).”
BackgroundChallenges in Beta Cell Replacement for Type 1 Diabetes
Lemos, J. R. N., & Skyler, J. S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000542206 · Cited by 20
“This includes the use of T-cell depletion (e.g., with antithymocyte globulin), calcineurin inhibitors to inhibit TCR signaling, antiproliferatives like mycophenolate to halt T-cell proliferation, and steroids to reduce in fl ammation [12, 15, 33, 34].”
Chang, C., Murphy, K., Kane, R. R., Lawrence, M. C., & Naziruddin, B. (2018) · Transplantation · doi:10.1097/tp.0000000000002287 · Cited by 20
Zazzeroni, L., Lanzoni, G., Pasquinelli, G., & Ricordi, C. (2017) · PubMed · Cited by 20
Self-citationSalama, B. F., Seeberger, K. L., & Korbutt, G. S. (2019) · Xenotransplantation · doi:10.1111/xen.12575 · Cited by 20
Islet cell transplantation in children
Balamurugan, A. N., Elder, D. A., Abu‐El‐Haija, M. A., & Nathan, J. D. (2020) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2020.150925 · Cited by 20
Triolo, T. M., & Bellin, M. D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.636824 · Cited by 20
“Even when insulin independence is not achieved, islet transplantation is highly successful in preventing severe hypoglycemia, if islet graft function is maintained (5, 14, 15).”
BackgroundSelf-citationCellular Immune Responses in Islet Xenograft Rejection
Hu, M., Hawthorne, W. J., Yi, S., & O’Connell, P. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.893985 · Cited by 20
“Existing islet allotransplant programs have demonstrated the proof of concept and successful transplantation leads to normal blood glucose control (1, 2).”
BackgroundEbrahimi, A. G., Jung, M.-H., Dreyfuss, J. M., Pan, H., Sgroi, D. C., Bonner‐Weir, S., & Weir, G. C. (2017) · Islets · doi:10.1080/19382014.2017.1283083 · Cited by 20
Artificial Pancreas or Novel Beta-Cell Replacement Therapies: a Race for Optimal Glycemic Control?
Nijhoff, M. F., & de Koning, E. J. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1073-6 · Cited by 20
Wong, J. M., & Pepper, A. R. (2024) · Frontiers in Transplantation · doi:10.3389/frtra.2024.1485444 · Cited by 19
“A Phase 3 clinical trial by Hering et al. found that infusing islets into the portal vein of forty-eight patients with brittle T1DM led to 87.5% achieving an HbA1c <7.0 with no severe hypoglycemic events at 1-year post-transplant and 71% of patients sustaining these criteria by 2 years (27).”
InfluentialLoganathan, G., Venugopal, S., Breite, A. G., Tucker, W. W., Narayanan, S., Dhanasekaran, M., Mokshagundam, S. L., Green, M. L., Hughes, M. G., Williams, S. K., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14542 · Cited by 19
Reprogramming Cells to Make Insulin
McKimpson, W. M., & Accili, D. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00040 · Cited by 19
“Regarding the former, results from a recent phase 3 clinical trial suggest that it may be possible to control glucose levels in individuals with T1D, complicated by severe hypoglycemia, using thismethod [13].”
BackgroundStephens, C. H., Morrison, R. A., McLaughlin, M. R., Orr, K. S., Tersey, S. A., Scott‐Moncrieff, J. C., Mirmira, R. G., Considine, R. V., & Voytik‐Harbin, S. L. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00066.2020 · Cited by 19
Building Biomimetic Potency Tests for Islet Transplantation
Glieberman, A. L., Pope, B. D., Melton, D. A., & Parker, K. K. (2021) · Diabetes · doi:10.2337/db20-0297 · Cited by 19
“The study successfully demonstrated the efficacy of islet transplantation for lowering HbA1c levels, drastically reducing the incidence of severe hypoglycemic events, and, in some cases, allowing for insulin independence (4,5).”
BackgroundInfluentialQuizon, M. J., & García, A. J. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-094846 · Cited by 19
Microwell bag culture for large-scale production of homogeneous islet-like clusters
Suenaga, R., Konagaya, S., Yamaura, J., Ito, R., Tanaka, S., Ishizaki, Y., & Toyoda, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-09124-w · Cited by 19
Fall in prevalence of impaired awareness of hypoglycaemia in individuals with type 1 diabetes
Ali, N., Hamdaoui, S. E., Schouwenberg, B. J., Tack, C. J., & de Galan, B. E. (2023) · Diabetic Medicine · doi:10.1111/dme.15042 · Cited by 19
“18,19 At the outpatient diabetes clinic of the Radboud University Medical Centre, we determined the prevalence of IAH among the type 1 diabetes population at regular intervals since 2006.”
BackgroundKaraoğlu, İ. C., Duymaz, D., Rashid, M. M., & Kızılel, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1618086 · Cited by 18
Moon, J. E., Lee, Y. N., Jeong, S., Jun, H. R., Hoang, M. H., Jo, Y., Jinah, J., Shim, I. K., & Kim, S. C. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03971-2 · Cited by 18
Advances in the Pathogenesis and Treatment Strategies for Type 1 Diabetes Mellitus
Du, M., Li, S., Jiang, J., Ma, X., Liu, L., Wang, T., Zhang, J., & Niu, D. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114185 · Cited by 18
The Last Mile in Beta-Cell Replacement Therapy for Type 1 Diabetes: Time to Grow Up
Piemonti, L. (2025) · Transplant International · doi:10.3389/ti.2025.14565 · Cited by 18
Yoon, I., Chung, H., Kim, H. J., Nam, H., Shin, J., Kim, Y., & Park, C. (2019) · Xenotransplantation · doi:10.1111/xen.12533 · Cited by 18
Microencapsulated islet-like microtissues with toroid geometry for enhanced cellular viability
Chen, Y., Nguyen, D. T., Kokil, G. R., Wong, Y. X., & Dang, T. T. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.08.018 · Cited by 18
Shaheen, R., Gurlin, R. E., Gologorsky, R. C., Blaha, C., Munnangi, P., Santandreu, A., Torres, A., Carnese, P., Nair, G. G., Szot, G. L., et al. (2021) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37236 · Cited by 18
Benefits and Hurdles of Pancreatic β-Cell Replacement
Bolla, A. M., Montefusco, L. B., Pastore, I., Lunati, M. E., Nasr, M. B., & Fiorina, P. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac058 · Cited by 19
Comparative Study of Two Common In Vitro Models for the Pancreatic Islet with MIN6
Chao, X., Zhao, F., Hu, J., Yu, Y., Xie, R., Zhong, J., Huang, M., Zeng, T., Yang, H., Luo, D., et al. (2023) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-022-00507-8 · Cited by 18
“This method allows 85% of recipients to be off insulin for at least 1 year as cadaveric pancreatic cells are harvested and infused into the portal vein [9].”
MethodThe future treatment for type 1 diabetes: Pig islet- or stem cell-derived β cells?
Naqvi, R. A., Naqvi, A. R., Singh, A. R., Priyadarshini, M., Balamurugan, A. N., & Layden, B. T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1001041 · Cited by 18
In vitro oxygen imaging of acellular and cell-loaded beta cell replacement devices
Kotecha, M., Wang, L., Hameed, S., Viswakarma, N., Ma, M., Stabler, C. L., Hoesli, C. A., & Epel, B. (2023) · Scientific Reports · doi:10.1038/s41598-023-42099-w · Cited by 18
Smood, B. F., Bottino, R., Hara, H., & Cooper, D. K. C. (2019) · International Journal of Surgery · doi:10.1016/j.ijsu.2019.07.032 · Cited by 18
“, exocrine) enriched cell preparations [3,28].”
BackgroundInfluentialSthijns, M. M. J. P. E., Jetten, M. J., Mohammed, S. G., Claessen, S. M. H., de Vries, R. H. W., Stell, A. L., de Bont, D. F. A., Engelse, M. A., Mumcuoglu, D., van Blitterswijk, C., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120449 · Cited by 18
Felix dies natalis, insulin… ceterum autem censeo “beta is better”
Piemonti, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01737-3 · Cited by 19
MYCL-mediated reprogramming expands pancreatic insulin-producing cells
Hirano, M., So, Y., Tsunekawa, S., Kabata, M., Ohta, S., Sagara, H., Sankoda, N., Taguchi, J., Yamada, Y., Ukai, T., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00530-y · Cited by 18
Pancreas transplant in type 1 diabetes mellitus: the emerging role of islet cell transplant
Kochar, I. S., & Jain, R. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2142012.006 · Cited by 17
Toni, T. D., Stock, A. A., Devaux, F., Gonzalez, G. C., Nunez, K., Rubanich, J. C., Safley, S. A., Weber, C. J., Ziebarth, N., Buchwald, P., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.886483 · Cited by 17
“For this reason, islet transplantation is currently limited to patients who suffer from severe and unstable T1D, have multiple episodes of hypoglycemia unawareness/glycemic lability, and are not capable of stabilizing the disease even with intensive insulin treatment including pumps and/or glucose-monitoring therapies…”
BackgroundMethodMu-u-min, R., Diané, A., Allouch, A., & Al-Siddiqi, H. (2025) · Biomedicines · doi:10.3390/biomedicines13020383 · Cited by 17
Loganathan, G., Venugopal, S., Narayanan, S., Tweed, B., Goedde, M., Gunaratnam, B., Tucker, W. W., Goli, P., Mokshagundam, S. L., McCarthy, R. C., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15111 · Cited by 17
“Multiple enzyme lots of collagenase ([1] 261160623, [2] 241180419, [3] 241170713) and BP‐protease ([1] 140724, [2] 150617, [3] 140115) from VitaCyte were used.”
MethodNanno, Y., Shajahan, A., Sonon, R. N., Azadi, P., Hering, B. J., & Burlak, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241249 · Cited by 17
“Phase 3 trials of transplantation of human pancreatic islets have highlighted the potential of cell replacement therapies in type 1 diabetes [1, 2].”
BackgroundSelf-citationBruni, A. D. C., Pepper, A. R., Pawlick, R. L., Gala-López, B., Gamble, A., Kin, T., Malcolm, A. J., Jones, C., Piganelli, J. D., Crapo, J. D., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14705 · Cited by 17
Self-citationScharp, D. W., Arulmoli, J., Morgan, K. N., Sunshine, H., & Hao, E. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1901052 · Cited by 17
Kuppan, P., Kelly, S. E., Seeberger, K. L., Castro, C., Rosko, M., Pepper, A. R., & Korbutt, G. S. (2022) · Polymers · doi:10.3390/polym14061120 · Cited by 17
Oh, B. J., Jin, S., Hwang, Y., Choi, J. M., Lee, H.-S., Kim, G., Kim, G.-S., Park, H. J., Kim, P., Kim, S. J., et al. (2018) · Diabetes · doi:10.2337/db17-0705 · Cited by 16
β‐Cell and renal transplantation options for diabetes
Flatt, A. J., Bennett, D., Counter, C., Brown, A. L., White, S. A., & Shaw, J. (2019) · Diabetic Medicine · doi:10.1111/dme.14177 · Cited by 16
Piemonti, L., Andrès, A., Casey, J., de Koning, E. J. P., Engelse, M. A., Hilbrands, R., Johnson, P., Keymeulen, B., Kerr-Conte, J. A., Korsgren, O., et al. (2021) · Transplant International · doi:10.1111/tri.13930 · Cited by 16
“It is also a decision consistent with the results obtained by four successful multicentre phase 3 clinical trials in islet transplantation recently published: CIT-07 (multicentre, single-arm) [1], CIT06 (pivotal trial) [2], TRIMECO (multicentre, open-label, randomized) [3] and REP0211 (multicentre, Double blind, rando…”
ResultSelf-citationLemos, J. R. N., Baidal, D. A., Poggioli, R., Fuenmayor, V., Chavez, C., Alvarez, A., Linetsky, E., Mauvais‐Jarvis, F., Ricordi, C., & Alejandro, R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab787 · Cited by 16
Self-citationWhole-Organ Pancreas and Islets Transplantations in UK: An Overview and Future Directions
Martin, D. J., Alberti, P., Demartines, N., Phillips, M., Casey, J., & Sutherland, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093245 · Cited by 16
“Glucose stability is obtained within days to weeks, but insulin independence (if it is achieved) is delayed for several months, as the isolated islets must engraft and revascularise in the new liver environment before reaching full functionality [62].”
BackgroundDelayed graft rejection in autoimmune islet transplantation via biomaterial immunotherapy
Coronel, M. M., Linderman, S. W., Martin, K. E., Hunckler, M. D., Medina, J. D., Barber, G. F., Riley, K., Yolcu, E. S., Shirwan, H., & García, A. J. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.07.023 · Cited by 16
Pancreatectomy, Islet Cell Transplantation, and Nutrition Considerations
Narayanan, S., Bhutiani, N., Adamson, D. T., & Jones, C. M. (2020) · Nutrition in Clinical Practice · doi:10.1002/ncp.10578 · Cited by 16
In Vivo Imaging of Pancreatic Islet Grafts in Diabetes Treatment
Arifin, D. R., & Bulte, J. W. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.640117 · Cited by 16
Exploring Novel Treatment Modalities for Type 1 Diabetes Mellitus: Potential and Prospects
Salama, R. A. A., Patni, M. A., Bahutair, S. N., Wadid, N. A., & Akikwala, M. S. (2024) · Healthcare · doi:10.3390/healthcare12151485 · Cited by 15
“Islet allotransplantation and pancreatic islet cell transplantation can restore insulin production, yet they are limited by donor availability, immune rejection, and the need for lifelong immunosuppression [71].”
BackgroundIslet transplantation in type 1 diabetes: moving forward
Forbes, S., Senior, P. A., & Shapiro, A. M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30107-4 · Cited by 15
Self-citationBiomarkers in Islet Cell Transplantation for Type 1 Diabetes
AlRashidi, F. T., & Gillespie, K. M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1059-4 · Cited by 15
β cell replacement therapy for the cure of diabetes
Lee, J., & Yoon, K. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13884 · Cited by 15
Chang, C., Bhagchandani, P., Poyser, J., Velasco, B. J., Zhao, W., Kwon, H.-S., Meyer, E. H., Shizuru, J. A., & Kim, S. K. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111615 · Cited by 15
“Transplantation of pancreatic islets from major histocompatibility complex (MHC)- mismatched (allogeneic) donors for diabetes after pancreatic β -cell loss is effective but requires chronic immunosuppression to prevent islet rejection (Bartlett et al., 2016; Hering et al., 2016).”
Decorin improves human pancreatic β-cell function and regulates ECM expression in vitro
Urbanczyk, M., Jeyagaran, A., Zbinden, A., Lu, C., Marzi, J., Kuhlburger, L., Nahnsen, S., Layland, S. L., Duffy, G. P., & Schenke‐Layland, K. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.12.005 · Cited by 15
Rojas‐Canales, D. M., Walters, S. N., Penko, D., Cultrone, D., Bailey, J., Chtanova, T., Nitschke, J., Johnston, J. K., Kireta, S., Loudovaris, T., et al. (2023) · Diabetes · doi:10.2337/db21-0841 · Cited by 15
Is islet transplantation a realistic approach to curing diabetes?
Jin, S., & Kim, K. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.224 · Cited by 15
“With the publication of the long-awaited report of the first phase 3 clinical trial, allogeneic islet transplantation is now transitioning from an experimental to a proven therapy with specific clinical indications [8].”
BackgroundAbadpour, S., Göpel, S., Schive, S. W., Korsgren, O., Foss, A. E., & Scholz, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-01805-1 · Cited by 15
Self-citationCho, B., Lee, E. J., Ahn, S. M., Kim, G., Lee, S. H., Ji, D.-Y., & Kang, J. T. (2019) · Transgenic Research · doi:10.1007/s11248-019-00169-8 · Cited by 15
JAK3 inhibitor-based immunosuppression in allogeneic islet transplantation in cynomolgus monkeys
Kim, J. M., Shin, J., Min, B., Kang, S., Yoon, I., Chung, H., Kim, J., Hwang, E., Ha, J., & Park, C. (2019) · Islets · doi:10.1080/19382014.2019.1650580 · Cited by 15
Kim, G., Lee, H. S., Oh, B. J., KWON, Y., Kim, H., Ha, S.-Y., Jin, S., & Kim, J. H. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16323 · Cited by 15
Lee, S.-J., Kim, H. J., Byun, N., & Park, C. (2020) · Cell Transplantation · doi:10.1177/0963689720913876 · Cited by 15
Alternative therapeutic strategies in diabetes management
Annicchiarico, A., Barile, B., Buccoliero, C., Nicchia, G. P., & Brunetti, G. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1142 · Cited by 14
“The CIT Consortium Protocol 07 (CIT-07) trial showed islet transplantation to be an effective treatment for subjects with impaired awareness of hypoglycemia and intractable severe hypoglycemic events[113].”
The future of islet transplantation beyond the BLA approval: challenges and opportunities
Wang, Y., McGarrigle, J. J., Cook, J., Rios, P., Monica, G. L., Chen, Y., Wei, W., & Oberholzer, J. (2025) · Frontiers in Transplantation · doi:10.3389/frtra.2025.1522409 · Cited by 14
Self-citationFernandez, S. A., Danielczak, L., Gauvin-Rossignol, G., Hasilo, C. P., Bégin‐Drolet, A., Ruel, J., Paraskevas, S., Leask, R. L., & Hoesli, C. A. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.674125 · Cited by 14
Lei, J., Zhang, A., Deng, H., Yang, Z., Peters, C. W., Lee, K. M., Wang, Z., Rosales, I. A., Rickert, C. G., & Markmann, J. F. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16875 · Cited by 14
Self-citationEstimation of Early Graft Function Using the BETA-2 Score Following Clinical Islet Transplantation
Lam, A. P., Oram, R. A., Forbes, S., Olateju, T., Malcolm, A. J., Imes, S., Shapiro, A. M. J., & Senior, P. A. (2022) · Transplant International · doi:10.3389/ti.2022.10335 · Cited by 14
“Derivation and validation of the BETA-2 score have previously been described (10).”
BackgroundSelf-citationMatsumura, M., Imura, T., Inagaki, A., Ogasawara, H., Fukuoka, K., Fathi, I., Miyagi, S., Ohashi, K., Unno, M., Kamei, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42720-x · Cited by 14
Clinical intraocular islet transplantation is not a number issue.
Shishido, A., Caicedo, A., Rodriguez‐Diaz, R., Pileggi, A., Berggren, P., & Abdulreda, M. H. (2016) · PubMed · Cited by 14
Advancements in transplantation therapy for diabetes: Pancreas, islet and stem cell
Nakamura, T., Fujikura, J., & Inagaki, N. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13358 · Cited by 14
Lau, H., Corrales, N., Rodriguez, S., Luong, C., Mohammadi, M. R., Khosrawipour, V., Li, S., Alexander, M., de Vos, P., & Lakey, J. R. T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243506 · Cited by 14
“Recently, T1DM patients who suffered from severe hypoglycemia despite the best medical treatment have been shown to have improved glycemic control, reduced severe hypoglycemic events, and enhanced awareness of hypoglycemia after islet allotransplantation in a phase 3 trial at eight islet transplantation centers in Nor…”
BackgroundPaep, D. L. D., Hulle, F. O. V., Ling, Z., Vanhoeij, M., Pirenne, J., Keymeulen, B., PIPELEERS, D. G., & Jacobs‐Tulleneers‐Thevissen, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251055 · Cited by 14
Mooranian, A., Ionescu, C. M., Wagle, S. R., Kovačević, B., Walker, D., Jones, M., Chester, J., Johnston, E., Đanić, M., Mikov, M., et al. (2021) · Cells · doi:10.3390/cells10092437 · Cited by 14
The Optimization of Short-Term Hepatocyte Preservation Before Transplantation
Fukuoka, K., Inagaki, A., Nakamura, Y., Matsumura, M., Yoshida, S., Imura, T., Igarashi, Y., Miyagi, S., Ohashi, K., Enosawa, S., et al. (2017) · Transplantation Direct · doi:10.1097/txd.0000000000000687 · Cited by 14
“Pancreatic islet transplantation is currently regarded as one of the treatment options for severe diabetes.(26) Considering that the clinical applications of HTx remain limited,(2,7) a number of experiences originating from islet transplantation, including cell isolation methods,(21,27,28) culture systems,(21,29) cell…”
BackgroundVoglová, B., Zahradnická, M., Girman, P., Kříž, J., Berková, Z., Koblas, T., Vávrová, E., Németová, L., Košinová, L., Habart, D., et al. (2017) · The Review of Diabetic Studies · doi:10.1900/rds.2017.14.10 · Cited by 14
Jawahar, A. P., Narayanan, S., Loganathan, G., Pradeep, J., Vitale, G. C., Jones, C. M., Hughes, M. G., Williams, S. K., & Balamurugan, A. N. (2018) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x13666180918092729 · Cited by 13
Matsumoto, S., Abalovich, A., Wynyard, S., Carulla, M. E., & Abalovich, D. (2023) · Xenotransplantation · doi:10.1111/xen.12798 · Cited by 13
Diagnosis and treatment of allograft rejection in islet transplantation
Landstra, C. P., Nijhoff, M. F., Roelen, D. L., de Vries, A. P. J., & de Koning, E. J. P. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.05.035 · Cited by 13
Oppler, S. H., Stone, L. H., Leishman, D. J., Janecek, J. L., Moore, M. E. G., Rangarajan, P., Willenberg, B. J., O’Brien, T. D., Modiano, J. F., Pheil, N., et al. (2024) · Science Advances · doi:10.1126/sciadv.adi4919 · Cited by 13
“Recent clinical trial publications on intraportal infusion of purified human pancreatic islet products have demonstrated long-term efficacy in T1DM ( 55 – 57 ); however, these protocols still require immunosuppression and invasive abdominal surgery for infusion.”
BackgroundCost and clinical outcome of islet transplantation in Norway 2010‐2015
Schive, S. W., Foss, A. E., Sahraoui, A., Kloster‐Jensen, K., Hafsahl, G., Kvalheim, G., Lundgren, T., von Zur‐Mühlen, B., Felldin, M., Rafael, E., et al. (2016) · Clinical Transplantation · doi:10.1111/ctr.12871 · Cited by 13
Self-citationForbes, S., Lam, A. P., Koh, A., Imes, S., Dinyari, P., Malcolm, A. J., Shapiro, A. M. J., & Senior, P. A. (2018) · Clinical Transplantation · doi:10.1111/ctr.13301 · Cited by 13
Self-citationImpaired hypoglycemia awareness in diabetes: epidemiology, mechanisms and therapeutic approaches
Klimontov, V. V. (2019) · Diabetes Mellitus · doi:10.14341/dm9597 · Cited by 13
Saeki, Y., Ishiyama, K., Ishida, N., Tanaka, Y., & Ohdan, H. (2019) · Scientific Reports · doi:10.1038/s41598-018-37395-9 · Cited by 13
Doering, L., Khatri, R., Petry, S. F., Sauer, H., Howaldt, H., & Linn, T. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1330-x · Cited by 13
Metadata
- Authors
- Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., Robien, M. A., Senior, P. A., Shapiro, A. M. J., Stock, P. G., Turgeon, N. A., & for the Clinical Islet Transplantation Consortium
- Affiliations
- University of Minnesota (US)
- University of Iowa (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of Wisconsin–Madison (US)
- Uppsala University (SE)
- Emory University (US)
- Northwestern University (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL
- University of California, San Francisco (US)
- University of Alberta (CA)
- Corresponding author
- Clarke, William R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-18
- Volume
- 39
- Issue
- 7
- Pages
- 1230-1240
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5317236
- OpenAlex
- W2341414956
- Cited by
- 645
- References
- 40
- Citations by year
- 2026: 25 · 2025: 51 · 2024: 47 · 2023: 67 · 2022: 75 · 2021: 88 · 2020: 60 · 2019: 79 · 2018: 73 · 2017: 60 · 2016: 20
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institute for Diabetes and Digestive and Kidney Diseases (U01-AI-089317, 1-AI-089316, 1-AI-065191, U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK-070460, U01-AI-065193, U01-DK-070430, U01-AI-065192)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, islet transplantation, severe hypoglycemia, hypoglycemia unawareness, glycemic control, HbA1c, immunosuppression, bleeding complications, glomerular filtration rate, donor-specific antibodies, renal function decline, islet autoimmunity
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Immunosuppression Therapy, Male, Middle Aged, North America, Islets of Langerhans Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.